The U.S. Food and Drug Administration told manufacturers that post‑market data do not support an increased risk of suicidal ideation or behavior tied to GLP‑1 receptor agonists approved for obesity. The agency requested removal of the suicide warning from the label warnings and precautions sections for Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide). FDA reviewers based the decision on a post‑market evaluation of adverse event reports and available clinical data. The move changes the risk profile communicated to prescribers and payers and may affect labeling negotiations, risk‑management plans and commercial positioning for obesity therapeutics.